Not medical advice. AICAR is sold for research. This guide does not recommend dosing, diagnosis, or therapy.
AICAR is listed in our catalogue under “Metabolic / Longevity.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.
AICAR (Acadesine) is an adenosine analog AMPK activator phosphorylated intracellularly to ZMP, an AMP-mimetic that regulates glucose and lipid metabolism.
Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.
“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.
Researchers study these compounds for mitochondrial function, nutrient sensing, and cellular energy stress responses -often in ageing or metabolic disease models.
Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.
Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.
Typical research dosing discussion (literature-style): 50–150 mg subcutaneous injection (research); 25–210 mg/kg IV (clinical) · 3–5 times weekly for research protocols; single-dose infusion in clinical settings · Human IV PK (25 mg/kg, 15-min infusion): total plasma clearance 2.2 ± 0.2 L/h/kg, plasma protein binding ~1%, blood/plasma ratio 1.0. Intact acadesine measurable in plasma for only 2 hours post-infusion. Terminal elimination t½ of total ¹⁴C-labeled metabolites approximately 1 week (uric acid as major metabolite). Poor oral bioavailability. WADA-prohibited substance since 2009 under S4.4 Metabolic Modulators.
For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.
What is AICAR in plain language?
AICAR is a research peptide we catalogue under “Metabolic / Longevity.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.
Does this page give medical advice or dosing instructions for AICAR?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.
Where can I see purity, variants, and pricing for AICAR?
Use the “View product” button to open the canonical shop listing for AICAR, where specifications and research SKU details are shown.
What about online case reports, before-and-after stories, or forum “logs” for AICAR?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.
Open the shop listing for variants, purity notes, and research SKU details.
View productAlso known as: AICAR, Acadesine, AICA Riboside, AICA-Riboside, Aminoimidazole Carboxamide Ribonucleoside, ZMP Precursor, 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside